Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, April 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 51 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 15,966 followers.

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease... https://t.co/q1T7BTFBF6 https://t.co/1LP9Dav6gO

Reply Repost Favourite

RT @Myeloma_Doc: #Kyprolis pharmacokinetics & saftey study in #myeloma pts w/ renal disease suggests no dose adjustment needed: https://t.c…

Reply Repost Favourite

RT @Myeloma_Doc: #Kyprolis pharmacokinetics & saftey study in #myeloma pts w/ renal disease suggests no dose adjustment needed: https://t.c…

Reply Repost Favourite

#Kyprolis pharmacokinetics & saftey study in #myeloma pts w/ renal disease suggests no dose adjustment needed: https://t.co/WLWVGD92UG. https://t.co/Mr3LWCoLg3

Reply Repost Favourite